News|Articles|March 23, 2023

CPHI Awards Open for Entries in Multiple Categories

Author(s)Jill Murphy

Three new awards have been added to the roster for 2023 and include some specific highlights that have occurred over the past few years.

The 20th CPHI Pharma Awards opened for entries on March 16, 2023, including three new categories to help reflect the increase in innovation in the industry.

The 2023 CPHI Pharma Awards are now open for entries and are set to celebrate global leaders across 12 categories, including development and manufacturing of devices and drugs, packaging, supply chain, sustainability, and regulatory compliance. Three new awards have been added to the roster for 2023 and include some specific highlights that have occurred over the past few years. For example, the new Start-up award was introduced to honor exhibitors from the start-up zone, and will span projects at proof-of-concept stage to prototype or commercial launch.

To further reflect wider efforts of many companies, the COVID Response category is being renamed the Accelerating Innovation award. The winner will be chosen based on innovations used to improve the impact of global healthcare emergencies or future health emergencies.

Lastly, the new Heart of Pharma award will celebrate the acceleration of social, ethical, and philanthropic activities. This will help to recognize the individuals, companies, or initiatives that have made the most noteworthy contributions to improving patient engagement or centricity, promoted corporate social responsibility and/or improvements to healthcare accessibility and equity.

The official list of CPHI Pharma Awards 2023 Categories:

Accelerating Innovation

API Development & Innovation

Finished Formulation

Manufacturing Excellence

Drug Delivery & Device Innovation

Packaging & Machinery

Supply Chain Excellence

Sustainability

Regulatory and Compliance

CEO of the Year

Start-Up Initiative

At the Heart of Pharma

To submit your entry, please visit the CPHI Pharma Awards website. Entries close on May 15, 2023.

Source: CPHI


Related to this article

CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.